

SEQENS'Lab

Press Release | Porcheville, 18 June 2019

SEQENS is unveiling its main innovation and development centre in the presence of Ms. Agnès Pannier-Runacher, Secretary of State to the Minister of Economy and Finance.

A 34,000-square-metre science platform, SEQENS'Lab offers a unique ecosystem, dedicated to our customers to accelerate their projects from the early research and development stages to production and sales. Pharmaceuticals, cosmetics and specialty ingredients are the key markets served by SEQENS. Close to Paris, SEQENS'Lab is the centre of excellence for developing a totally unique package of R&D services.

SEQENS'Lab is a development accelerator, dedicated to our customers

As an R&D centre that meets the highest standards, SEQENS'Lab has assembled the group's key skills and expertise in recognised areas of excellence, such as: organic chemistry development at the forefront of the latest innovations, two referring laboratories in Physics & Solid-State Chemistry as well as in Process Safety, kinetic and thermodynamic simulation tools, large batch manufacturing capabilities for preclinical and clinical studies, all in an environment that adheres to cGMP.

Furthermore, it has innovative means for developing future processes, particularly in flow chemistry, that are more productive and energy-efficient and have minimal environmental impact.

Innovative SMEs and start-ups that are specialised in analytical services and CROs will be hosted at SEQENS'Lab, giving our customers access to complementary skills in one place. The example of GenEvolution demonstrates this: partner from the very beginning, it brings key skills to SEQENS'Lab in toxicology for medicine, chemical ingredients, plant extracts and cosmetic ingredient evaluation thanks to the miniaturization of its in-vitro tests.

SEQENS'Lab is an appealing and modern place, it reflects the group's development dynamic

With SEQENS'Lab, we aim to also facilitate collaboration amongst our teams in a modern and appealing location, designed for carrying out our customers' projects more effectively and efficiently. Three main principles make up its definition:

- Create a dynamic ecosystem facilitating collaboration between SEQENS teams, innovative SMEs and academic partners;
- Gather in one place multidisciplinary teams with the skills needed to complete our customers' projects;
- Create an attractive and modern space, a reference point and a showcase for our customers.

"The SEQENS'Lab is dedicated to our customers and accelerating their projects. It is also dedicated to our teams, this centre is theirs too. SEQENS currently has a world-class innovation and development centre." explained Pierre Luzeau, SEQENS group CEO.

"The SEQENS' Lab will also welcome external resources, innovative start-ups and our historic partners, forming a dynamic and cohesive ecosystem in service of innovation. We also want to facilitate interactions with our academic partners and create a LabCom with CNRS (French National Centre for Scientific Research) to design and develop highly innovative solutions," added Christophe Eychenne-Baron, R&D director.

About SEQENS

SEQENS is an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering custom-made products and solutions to its customers.

Unique expertise to develop and produce highly complex molecules

Seqens' mission is to bring R&D and industrial performance to our clients' projects with a unique skill set and a broad continuum of technologies.

Science is its core business

Seqens operates 24 industrial plants and 3 R&D centers in Europe, North America and Asia. More than 300 scientists, engineers and experts develop tailor-made solutions for its customers and ensure that products are successfully transferred into production.

An integrated partner in pharmaceutical synthesis and specialty ingredients

In the pharmaceutical industry, Seqens supports its customers for the development, scale-up and manufacturing of drug substances from preclinical through to commercial phase and offers a large portfolio of APIs and proprietary products. Seqens also develops custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare.


Entrepreneurship, reliability and responsibility

Driven by a culture of excellence and a strong entrepreneurial spirit, the 3,200 SEQENS employees are committed to providing our customers with the highest level of service and high quality products. SEQENS is committed to developing its business sustainably and responsibly and continuously improving its SD-CSR program (Sustainable Development and Corporate Social Responsibility).

For more information about www.seqens.com

Contact SEQENS: Aline Rancony Aline.rancony@seqens.com

(+33) 6 79 18 53 92



CONTINUUM OF PROGRESS

SEQENS

With capital of 35,232,819.63 euros - 21 chemin de la Sauvegarde "21 Ecully Parc" - CS 33167 69134 ECULLY Cedex - 444 465 736 RCS Lyon